Found 8 matching trials
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors PHASE2 This is a multicenter, multi-arm trial evaluating anti-tumor activity, safe...
Show More Learn More & Join Trial
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC PHASE2 A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy o...
Show More Learn More & Join Trial
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) PHASE3 Phase 3, multicenter, international, open-label, randomized, 2-arm trial in...
Show More Status
Active Not Recruiting
Location
Mid Florida Hematology and Oncology Center
Learn More & Join Trial
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma PHASE1 Combination therapy is becoming more and more general in the treatment of o...
Show More Learn More & Join Trial
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. PHASE2 The purpose of this project is to realize a randomized open-label study (Eu...
Show More Location
Cliniques Universitaires Saint-Luc
Learn More & Join Trial
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer PHASE1 This phase I trial tests the safety and side effects of a PD-L1/IDO peptide...
Show More Status
Active Not Recruiting
Location
University of California Davis Comprehensive Cancer Center
Learn More & Join Trial
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma PHASE2 The researchers are doing this study to find out whether the study vaccines...
Show More Status
Active Not Recruiting
Location
Hartford Healthcare Alliance (Data Collection Only)
Learn More & Join Trial
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC PHASE1 The purpose of this study is to determine if IO102 combined with pembrolizu...
Show More Location
Thoraxklinik Heidelberg gGmbH
Learn More & Join Trial